NZ255870A - Composition of a peptide comprising receptor-binding, cytoplasmic translocation and nuclear translocation domains and its use as a translocation signal delivery system for macromolecules - Google Patents

Composition of a peptide comprising receptor-binding, cytoplasmic translocation and nuclear translocation domains and its use as a translocation signal delivery system for macromolecules

Info

Publication number
NZ255870A
NZ255870A NZ255870A NZ25587093A NZ255870A NZ 255870 A NZ255870 A NZ 255870A NZ 255870 A NZ255870 A NZ 255870A NZ 25587093 A NZ25587093 A NZ 25587093A NZ 255870 A NZ255870 A NZ 255870A
Authority
NZ
New Zealand
Prior art keywords
domain
dna
translocation
polypeptide
composition
Prior art date
Application number
NZ255870A
Other languages
English (en)
Inventor
Thomas R Barnett
Rathindra C Das
Original Assignee
Bayer Corp Formerly Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp Formerly Miles Inc filed Critical Bayer Corp Formerly Miles Inc
Publication of NZ255870A publication Critical patent/NZ255870A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Formation Of Insulating Films (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ255870A 1992-08-25 1993-08-24 Composition of a peptide comprising receptor-binding, cytoplasmic translocation and nuclear translocation domains and its use as a translocation signal delivery system for macromolecules NZ255870A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93507492A 1992-08-25 1992-08-25

Publications (1)

Publication Number Publication Date
NZ255870A true NZ255870A (en) 1996-09-25

Family

ID=25466554

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ255870A NZ255870A (en) 1992-08-25 1993-08-24 Composition of a peptide comprising receptor-binding, cytoplasmic translocation and nuclear translocation domains and its use as a translocation signal delivery system for macromolecules

Country Status (10)

Country Link
EP (1) EP0658210A1 (fr)
JP (1) JPH08504565A (fr)
KR (1) KR950703650A (fr)
AU (1) AU674026B2 (fr)
CA (1) CA2143308A1 (fr)
FI (1) FI950866A (fr)
IL (1) IL106760A (fr)
NZ (1) NZ255870A (fr)
WO (1) WO1994004696A1 (fr)
ZA (1) ZA936189B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
WO1994023751A1 (fr) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Peptides de tranfert d'acides nucleiques et leur utilisation pour injecter des acides nucleiques dans des cellules eucaryotes
EP0745134A1 (fr) * 1994-02-22 1996-12-04 Danafarber Cancer Institute Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2187818A1 (fr) * 1994-04-15 1995-10-26 Robert W. Overell Proteine de fusion d'apport de gene
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
DE69521331T2 (de) * 1994-11-01 2001-09-20 Winfried Wels Nukleinsäure-einbringungssystem
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
ATE229977T1 (de) * 1996-03-26 2003-01-15 Razvan T Radulescu Peptide mit antiproliferativen eigenschaften
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
WO1998042876A1 (fr) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methodes et compositions recourant a des proteines transmembranaires pour transporter des materiaux a travers la membrane de cellules
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
WO1999007723A1 (fr) * 1997-08-07 1999-02-18 University Of Maryland, Baltimore Vehicule de fixation d'apport d'acide nucleique
WO2000027795A1 (fr) 1998-11-12 2000-05-18 Invitrogen Corporation Reactifs de transfection
AU2983100A (en) * 1999-02-06 2000-08-25 Aurx, Inc. Drug delivery vehicle
DE19910419A1 (de) * 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
US6387684B1 (en) * 1999-09-13 2002-05-14 Academia Sinica Topoisomerase 1-mediated DNA delivery
JP2004500047A (ja) * 1999-10-20 2004-01-08 ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン キメラ免疫原性組成物およびこれらをコードする核酸
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
ES2454640T3 (es) 2000-08-03 2014-04-11 Johns Hopkins University Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002083166A1 (fr) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Complexes de polymeres d'interferons et leur utilisation medicinale
EP1947116B1 (fr) * 2003-02-10 2017-06-21 2-BBB Medicines B.V. Acides nucléiques exprimés par action différentielle dans la barrière hématoencéphalique sous des conditions inflammatoires
EP1644048B1 (fr) 2003-05-05 2015-04-29 Johns Hopkins University Vaccin a adn anti-cancer faisant appel a des plasmides codant une sequence-signal, un antigene oncoproteine mutant, et une proteine de choc thermique
EP1697534B1 (fr) 2003-12-01 2010-06-02 Life Technologies Corporation Molecule d'acide nucleique contenant des sites de recombinaison et leurs procedes d'utilisation
CA2594040A1 (fr) 2005-01-06 2006-07-13 The Johns Hopkins University Interference arn bloquant l'expression de l'immunite potentialisee de proteines pro-apoptotiques induite par adn et des vaccins de cellules dendritiques transfectes
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20110110901A1 (en) * 2008-07-18 2011-05-12 Chee Keong Choo Methods of long-term culture of eukaryotic cells and uses thereof
WO2016011203A1 (fr) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658818B2 (en) * 1989-12-21 1995-05-04 Johns Hopkins University School Of Medicine, The Method of delivering molecules into eukaryotic cells using tat protein conjugate
CA2092319A1 (fr) * 1990-09-25 1992-03-26 George Y. Wu Expression prolongee de polynucleotides introduits dans une cellule
DE4139001A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen
WO1993017102A1 (fr) * 1992-02-19 1993-09-02 The Trustees Of The University Of Pennsylvania MODULATION DE FONCTIONS CELLULAIRES AVEC DES PROTEINES HnRNP
CA2131620A1 (fr) * 1992-03-20 1993-09-30 Louis C. Smith Systeme de transport de l'adn et mode d'emploi

Also Published As

Publication number Publication date
EP0658210A1 (fr) 1995-06-21
AU5088593A (en) 1994-03-15
CA2143308A1 (fr) 1994-03-03
IL106760A0 (en) 1993-12-08
FI950866A (fi) 1995-04-24
KR950703650A (ko) 1995-09-20
ZA936189B (en) 1995-01-10
AU674026B2 (en) 1996-12-05
IL106760A (en) 1999-12-31
FI950866A0 (fi) 1995-02-24
WO1994004696A1 (fr) 1994-03-03
JPH08504565A (ja) 1996-05-21

Similar Documents

Publication Publication Date Title
AU674026B2 (en) Translocation signal facilitated nuclear delivery of macromolecules
US11998635B2 (en) Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
US6498233B1 (en) Nucleic acid transfer system
Schwartz et al. Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo
AU785007B2 (en) Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
JP4697982B2 (ja) モジュラートランスフェクション系
Wagstaff et al. Nucleocytoplasmic transport of DNA: enhancing non-viral gene transfer
Medina-Kauwe et al. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins
US6720310B1 (en) Transfer method for specific cellular localization of nucleic acids
Min et al. Gene delivery using a derivative of the protein transduction domain peptide, K-Antp
Chan et al. Enhancement of MSH receptor-and GAL4-mediated gene transfer by switching the nuclear import pathway
US6740524B1 (en) Nucleic acid transfer phage
NZ521563A (en) Peptide conjugates for drug delivery
EP1053024A1 (fr) Fusion de liposome et vehicule d'administration
Sloots et al. Recombinant derivatives of the human high‐mobility group protein HMGB2 mediate efficient nonviral gene delivery
WO2007061762A2 (fr) Complexe de transfert de genes non viral
Hellgren et al. Factors controlling the efficiency of Tat-mediated plasmid DNA transfer
AU2020310380A1 (en) Complex for intracellular delivery of molecules
US20230391836A1 (en) Amino acid sequence that can destroy cells, and related nucleotide sequence and related uses thereof
AU749113B2 (en) Compositions and methods for highly efficient transfection
Tachibana et al. pH-sensitive Liposomes in nuclear targeting of macromolecules
Ziady et al. Receptor-directed molecular conjugates for gene transfer
Ning A bioresponsive peptide as a single component gene vector
Rolland et al. Pharmaceutical gene medicines for non-viral gene therapy
Balicki Gene transfer mediated by histone H2A

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)